CRISPR and Cancer

Last week, Vor Bio announced new, encouraging clinical data from the ongoing Phase 1/2 VBP101 trial of trem-cel followed by the anti-CD33...

Researchers in Italy report a new nanoplatform for IL-30 knockout as a novel therapeutic strategy for metastatic prostate cancer.

Italian scientists have demonstrated the potential of a targeted CRISPR-Cas9 delivery system to suppress tumour growth and metastasis in prostate...

A CRISPR-based screen has revealed that the transcription factor ZNF740 plays a pivotal role in determining the sensitivity of acute myeloid leukaemia...

Italian researchers have used CRISPR-Cas9 screening to identify long non-coding RNA (lncRNA) RP11-350G8.5 as a key oncogenic factor in multiple...

Using CRISPR-Cas9 to knock out CD5, researchers have significantly improved the efficacy of adoptive T-cell therapies for both haematological and...

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...

Based on an evolved bacterial adenosine deaminase, DECOR represents a significant advancement in RNA editing technology by providing a more precise,...